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Summary: A new phosphate-binding agent which does not cause any severe side effects in vivo was developed
by modifying a crosslinked dextran with polynuclear iron(III)oxide-hydroxide. Its particle size ranges from 150 to
300 , and the iron content was about 18% by dry weight. The oxidation state of iron was characterized by ESCA
and Mössbauer spectroscopy. The maximum phosphate binding capacity of the iron(III)oxide-hydroxide-modified
dextran was determined with respect to aqueous phosphate Solutions, human serum and whole blood. The effects
on whole blood count, haemolysis, protein concentration and enzyme activities were examined. In addition, the
influence of phosphate concentration, pH and temperature on the phosphate uptake of the material was determined.
The results show that this new adsorbent might provide an alternative to conventional phosphate-binding agents.
This paper also describes the first experiments on the therapeutic application of the material in an extracorporeal
blood perfusion System for the treatment of hyperphosphataemia during haemodialysis.
Introduction lopathy and osteomalacia. The use of calcium com-
T , . 1 j C . , , , . , , pounds is associated with gastrointestinal problems suchIn chromc renal faüure phosphorus retentioii and hyper- ,.' .,, r . , , . , . , ^,
, ,
 4 . , · i · t 'j i * j äs diarrhoea or mild constipation and a high nsk of hyp-phosphataerma play a major role in the development and , . ^ ' *, . , , - ,
. , ~ , , ., .,. - ercalcaemia. The dosage of magnesium hydroxide äs an
mamtenance of secondary hyperoarathyroidism and os- , . , , , . , . , . . , ,
teodystrophy (1-3). Neitber an adequate diet nor effi- alt^atlve PhosPhate binder 1S hmited by the serum
cient dialysis are usually sufficient to prevent pathologic ««eneiiüm concentration. In addition, this agent alone
phosphate concentrations in the blood (4). Antacids such has Proved i°ade^ate ** the e"act contro1 of serum
äs A1(OH)3 or CaCO3 possess the capacity to adsorb P^sphate (10). Current therapies include reduction of
Phosphate. However, aptacids presently used for that ^^ Phosphate intake, reduction of phosphate absorp-
purpose are quite inefficient in binding phosphate in tion in Äe intestine by Ph«sphate binding agents, and
vivo, although aluminum- or calcium-containiag com- «öianqed removal of phosphate from the body through
pounds are orälly administered in large amounts (5, 6). »«>« efficient dialysis techniques. The recommended in-
The inefficiency of cofnmonly-used phosphate binders take of phosphate should not exceed 32 mmol (1000 mg
creates a clinical dilemma, since the control of hyper- p) Per day in adults and should be reduced for children
phösphataemia requires increased doses, which result in according to their age. With highly specialized diets, the
a higher riskof toxieily. This includes bone disease, alu- intake of phosphorus can be reduced to less than 16
minum dementia from aluminum containing antacids (7, mmol (500 mg P) per day (11). In patients with mildly
8), and hypercalcaemia, äs well äs soft tissue calcifica- increased serum phosphate concentrations, haemodialy-
tion from antacids containing calcium (9). The increased sis removes about 8 mmol (252 mg P) of phosphate per
tissue content of aluminum appears to be an important day with three treatments per week. Continuous ambula-
factor in the pathogenesis of dialysis-related encepha- tory peritoneal dialysis even removes about 10 mmol
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(324 mg P) per day (12). These rates of removal, how-
ever, are still insufficient. Hence, most patients with
end-stage renal failure require phosphate binders.
Recently we developed a novel phosphate-binding agent
by coupling polynuclear iron(III) oxide-hydroxide to
crosslinked dextran (13). In addition to its oral applica-
tion, this material has the potential to serve äs a phos-
phate adsorbent in extracorporeal perfusion Systems for
the treatment of hype hosphataemia.
Materials and Methods
Preparation of phosphate adsorbent
Starting material for the preparation of an insoluble iron(III)oxide-
hydroxide porous support was the crosslinked dextran Dormagel N
25 C™ (Pfeifer and Langen, Dormagen, Germany). Dormagel™
is a spherical, neutral, soft gel cross-linked by epichlorhydrin. The
molecular cut-off of the unmodified material corresponds to Mr
= 6000, and the particle size is 150-300 . The pH stability
ranges from 2 to 12, and the swelling capacity is 4—6 ml/g.
For chemieäl modiflcation according to I.e. (13) the material was
suspended in a 50% solution of FeCla · 6 H2O. This mixture was
then added under vigorous stirring to l mol/1 sodium hydroxide
solution. The modified gel beads were collected by filtration and
washed with water to neutrality. Sterilization was carried out at a
temperature of 121 °C according to F015 conditions üsing an auto-
clave (type GETING GEV 112) (14).
Test Solutions
Standardized phosphate solution: 10 mmol/1 NaCl, 4 mmol/1 KC1,
0.5 mmol/1 Na2SO4, 1.6 mmol/1 Na2HPO4 - 2 H2O, 1.6 mmol/1
NaH2PO4 · 2 H2O (pH 7.4).
Standardized calcium solution: 50 mmol/1 Tris, 2.5 mmol/1 CaCl2
• 2 H2O, 10 mmol/1 NaCl, 4 mmol/I KC1, 0.5 mmol/1 Na2SO4 (pH
7,4).
Blood and plasma: Fresh blood from pigs was obtained from the
slaughter house in Melsungen and human blood was provided by
the DRK blood bank, Kassel. For stabilization, heparin (6000 IU/1)
was added. The blood was centrifuged for 10 min at 4500 min"1
to separate blood cells from plasma.
Determination of enzymes and electrolytes
Enzyme activities of glutamate oxaloacetate transaminase, gluta-
mate pyruvate transaminase, lactate dehydrogenase, and alkaline
phosphatase were determined according to Standard methods, de-
scribed by Rick (15). Phosphate, calcium, magnesium, iron, and
protein concentrations in serum, plasma or aqueous Solutions were
photometrically determined according to Standard protocols (16—
18).
The iron content of the adsorbent was determined by atomic ab-
sorption (AAS) (19), and its phosphate concentration by indüc-
tively coupled plasma spectroscopy (ICP) (20).
Physical characterization
Scanning electron microscopy of the adsorbent was performed on
a SEM XS 40 (ABT, Japan) at 20 kV. The magnification for the
uncoated and the modified dextran beads was in the ränge of 100-
3000-fold. Electron micrographs were taken with an Asanuma
Camera (Mechanical Laboratory & Co, Japan) using a Polaroid
Film Type 52 (400 ASA/27 DIN). ESCA (electron spectroscopy for
chernical analysis), Mössbauer and magnetic measurements were
kindly performed by Drs. J. Knecht and J. Pebler, Fachbereich
Chemie, University of Marburg.
In vitro perfusion experiments
In vitro tests with Standard Solutions, plasma, or blood were carried
put äs follows. Glass colurrins (Bip-Rad, 120 X 10 mm) were
packed with 3 ml of the adsorbent arid equilibrated with Tris buffer
pH 7.4. Standard phosphate solution or plasma was pumped
throügh the columns by means of a roiler pump (Intusomat, B.
Braun Melsungen AG) at a flow rate of l ml/min. After collectipn
of 4 rril pre-eluate, samples were drawn from the eluate ,at various
time interväls. Phosphate, iron, calcium, glucose, heparin, and en^
zymes were determined in the samples. For the analysis of plasma
the reservoir was kept in a shaking bath at 37 °C.
To determine the maximal binding eapacity, aqueous phosphate so-
lution, blood or plasma was circulated for 18 h at a rate pf l ml/
min thrpugh a column containing 3 ml adsorbent. The material was
then washed with 100 ml distilled water to remove unbound phos^
phate, dried at 60 °C> and analysed for phosphate äs described
above.
For adsorption experiments with blood, a cylindrical Makroion™
cartridge (volume: 250 ml) was used. The column inlet and outlet
were closed by sieves with a mesh size of 94 . EDTA-stabilized
blood (500 ml) was circulated throügh the cartridge at a flow rate
of 100 ml/min. The blood reservoir was kept in a shaking bath
at 37 °C.
In vivo perfusion tests
In vivo experiments were carried out with locally anaesthetized
female sheep in the laboratory of the Experimental Surgery deparl·
ment (B. Braun Melsungen AG) according to an officially licensed
protocol. Cartridges (250 ml) were slurry-packed with adsorbent
and integrated in a dialysis circulation unit (HD secura, B. Braun
Melsungen AG). Equilibration of the adsorbent and prewashing of
the tubing System was carried out by circulating with 9 g/l sodium
Chloride solution. A conventional dialysis solution (acetate concen-
trate, 35 mmol/1) was used. To prevent fibrin clotting during ther-
apy, heparin (10000 lU/h) was administered to the sheep.
Results
Characterization of the adsorbent
Reaction of the insoluble, crosslinked dextran matrix
with a concentrated FeCl3 solution at high pH led to an
iron uptake of 160—210 g/kg ünder our Standard reac-
tion conditions. A stable product was obtained after
washing with deionized water to neutrality. Drying, heat
Sterilization, prolonged passage of phosphate Solutions,
or contact with blood did not result in any leaching or
loss of iron from the material, Although the uniform
surface of the untreated gel beads became rough and
vaulted in the iron-coated spheres (fig. 1) the material
could without difficulty be handled in flow-through col-
umns or cartridges.
X-ray dif&action indicated the complete absence of
crystalline structures in the solid. The binding energies
of iron and oxygen in the compound, determined by X-
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Fig. l Scanning electron micrographs of dextran (Dormagel N25C) adsorbent. Lefl: Unmodified.
Right: Iron(III)oxide-hydroxide-modified (Fe: 188 g/kg). Magnification, 100-fold.
ray photoelectron spectroscopy (ESCA), were 710.5 eV
(Fe2p3/2) and 535.4 eV (OiS), respectively, in close
agreement with the values found in Fe(OH)3 and other
reference compounds (21). M ssbauer and magnetic
susceptibility measurements revealed the presence of
high-spin Fe3"1" ions in a slightly distorted environment,
and an effective magnetic moment of μβίτ = 5.9 μΒ· All
these data confirm that the oxidation state of the metal
in the iron-modified dextran is exclusively -f III.
Phosphate adsorption characteristics
Uptake of phosphate from a Standard solution is shown
in figure 2. Iron-dextran complexes with an iron content
between 190 and 210 g/kg reve led the highest phos-
Tab. l Iron content and phosphate adsorption capacity of iron-
dextran complexes.
10 20 30 40 50 60 70 80 90 100 120 140 160
Phosphate solution [ml]
Fig. 2 Removal of phosphate from a Standard solution. Columns
packed with 3 inl of ironrdextran adsorbent (iron: 188 g/kg) were
perfused at l ml · min"1 flow rate and the phosphate content of
the eluate was determined. Tlie horizontal line represents the initial
concentration (Pj, 100 mg/1). A: Dried adsorbent, not sterilized. ·:
Dried material sterilized at 121 °C.
Product
No.
4
5
3
8
2
1
6
7
Preparation
conditions
reaction at pH 6
Standard
Standard
Standard
Standard
Standard
FeCl3 repeated
FeCl3 repeated
Iron
content
(g/kg)
84
157
188
199
203
211
255
293
Phosphate
adsorption
(mmol/1)
56
71
74
84
88
89
85
85
Phos-
phorus
content
.(g/kg)
4.0
5.1
5.3
6.0
6.3
6.4
6.1
6.1
phate binding capacity (tab. 1). Higher amounts of iron,
produced by repeated treatment of the adsorbent in
FeCl3 solution, did not raise the phosphate binding ca-
pacity. In equilibrium binding experiments, sterile adsor-
bents coated with 210 g/kg iron typically bound 250
mmol (7.7 g) Pj per kg or 90 mmol (2.6 g) P{ per litre
adsorbent. These values were obtained by equilibrating
3 ml of sterilized adsorbent in a column for 18h with
500 ml circulating phosphate Standard solution, fol-
lowed by removal of unbound inorganic phosphate by
washing the column with 50 ml distilled water. Absorp-
tion of phosphate from an aqueous solution onto the
iron-dextrari complex could also be monitored by 31P-
NMR (not shown).
The phosphate adsorption capacity was generally re-
duced about 30% after heat sterilization (fig. 2). On the
other hand, heat sterilization ppears to lead to a stabi-
lized iron(III) oxide-hydroxide modified dextran at
acidic pH vaiues. Thus, the sterilized adsorbent does not
liberale iron even around pH 2.
Eur. J. CKn. Chem. Clin. Bioohem. / Vol. 32,1994 / No. 10
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Perfasion of 3 ml adsorbent (950 mg dry weight, iron
content 157 g/kg) with 100 ml human plasma resulted
in the binding of 2.04 g phosphorus per litre gel which
corresponds to a 74% reduction of the phosphate content
(fig. 3). No alterations of the protein and iron(III) con-
centration, or of distinct enzyme activities were ob-
served during the treatment. The profile of the elimina-
tion curve shows that additional phosphate can be ad-
sorbed when higher blood phosphate concentrations are
present.
Investigation of the haemocompatibility of the adsorbent
in a 250 ml-cartridge showed that the phosphate concen-
tration of circulating whole blood decreased from 1.1
mmol/1 to 0.09 mmol/1 (3.4 mg/dl to 0.3 mg/dl PI). At a
flow rate of 100 ml/min, a pressure of 80 mbar was built
up. Even after 25 circulations the material did not induce
haemolytic reactions, and there were no significant alter-
ations in common blood quantities äs shown in table 2.
• \
Elimination of calcium ions
The behaviour towards calcium ions was determined by
perfusing the adsorbent in a 3 ml column with 100 ml
of human serum, heparinized plasma or standardized
calcium solution (fig. 4). Calcium was only bound to
the adsorbent in the presence of phosphate but not in
phosphate-free solution. A molar ratio of calcium and
phosphate elimination of approximately l : l was
reached when both concentrations were varied.
In vivo experiments
The iron(III)oxide-hydroxide dextran adsorbent was
tested in extracorporeal apheresis experiments with
sheep. Laboratory data are reported in table 3. The aim
of these tests was to investigate functional aspects such
0.2
40 50 60 70
Human plasma [ml]
90 100
Fig. 3 Elimination of phosphate from 100 ml human plasma (ini-
tial P content, 2.8 mg). Conditions äs in Fig. 2.
as handling, flow rate, pressure, and the influence on
important quaiitities such as haemocompatibility, whole
blood count, and the concentrations of phosphate,
calcium and iron. The application of the adsorbent
caused an efficient and significant decrease of the post-
cartridge phosphate concentratiqn from 1.93 mmol/1 (6,0
mg/dl) to 0.06 mmol/1 (0.2 mg/dl) Pf at the end of treat-
ment (l h dialysis). There was neither an increase iii the
iron nor a decrease in the calcium concentration öf the
blood during treatnient with conventional dialysis solu-
tions containing calcium. By appropriate dosage of hep-
arin, the flow rate and pressure could be kept at normal
levels without inducing haemolysis or significant alter-
ations of the blood cells. Only thrombocytes were fe-
duced during treatment. This was possibly due to some
fibrin clotting which was not observed in in vitro experi-
ments.
Discussion
Patients with kidney diseases, especially those with
chronic renal failure, who have been on haemodialysis
for a lofig time, often have Symptoms ässociated with
highly elevated concentrations of inorganic phosphate in
the blood. Lafge amounts of phosphate äbove normal
levels (0.6—1.3 mmol/1) result in a decrease of calcium
ion concentration which in turn induces the parathyroid
to secrete an excess amount of parathyroid hormone.
The hormone increase and the inability of the diseased
kidney to hydroxylate 25-hydroxycholecalciferol to the
active forms of vitamin D are the principal biochemical
factors underlying most of the related Symptoms (22,
23). In the case of chronic renal failure the filtration
rate of glomeruli is less than 8-10 ml/min. Pathological
phosphate concentrations ranging between 2.25 and
3 mmol/1 normally decrease to 1.3 — 1.6 mmol/1 after
haemodialysis (24). In this context, it has recently been
shown that extracorporeal elimination of phosphate is
more effective usihg Standard dialysers than high-flux-
dialysers (7! Eisenhauer, C. Ronco, unpublished). This
effect is due to the limited phosphate concentration in
the blood. Thus, the intravascular phosphate concentra-
tion rather than the clearaiice seems to be rate-limiting.
The phosphate clearance, for exatnple of the Diacap cap-
illary dialyser (B. Braun, Melsungen, Germany) lies be-
tween 93 and 150 ml/min when pumping blood at 200
ml/min and dialysis solution at 500 ml/min.
The phosphate intake of a patient is 32 mmol per day or
about 224 mmol per week. During one dialysis Session
about 32 mmol phosphate are normally eliminated (4).
These rates of removal äfe insüfficient to prevent hyper-
parathyroidism. The 8 5 »of about 130 minol phos-
phate per week has to be addftionally elimiiiatedv Hence,
Eur. J. Clin! Chem. CHn. Biochem. / Vol. 32, 1994 /No. 10
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1
Tab. 2 Blood count and erytlirocyte characteristics during perfusion of iron-dextran phosphate
adsorbent with human blood.
Quantity
Leukocytes (109/1)
Erythrocytes (10I2/1)
Haemoglobin (g/l)
Haematocril (fraction)
MCV (fl)
HbE (pg)
MCHC (g/l)
Thrombocytes (109/1)
Lymphocytes (%)
Monocytes (%)
Segm. granulocytes (%)
Eosinophiles (%)
Basophiles (%)
Number of passages
0
4.9
4.4
125
0.392
89.7
28.5
318
264
29
3
62
3
1
2
5.1
4.5
126
0.399
89.0
38.0
315
273
30
—66
4
—
4
5.0
4.4
126
0.395
88.9
26.3
318
270
32
1
63
2
—
6
5.0
4.4
126
0.391
88.4
28.5
322
257
33
3
59
1
1
8
4.9
4.5
127
0.395
88.3
28.5
324
269
30
5
63
1
1
10
5.2
4.4
126
0.390
87.8
28.4
324
269
30
5
63
1
1
12
4.9
4.5
127
0.390
87.4
28.5
324
267
35
4
53
3
—
16
5.2
4.3
124
0.375
86.9
28.8
331
272
27
4
61
8
—
20
4.9
4.3
124
0.374
86.7
28.7
331
266
27
4
65
4
—
24
4.7
4.3
125
0.373
86.8
26.7
330
256
31
5
60
4
—
25
4.9
4.5
124
0.371
86.5
29.0
335
270
30
6
62
2
—
A cartridge containing 250 ml phosphate adsorbent was perfused
at 100 ml · mfcr1 under recirculating conditions with 500 ml hu-
man blood containing 7 mmol/1 EDTA.
MCV = Mean corpuscular volume
H DE = Haemoglobin content per erythrocyte
MCHC = Mean corpuscular haemoglobin concentration
3
10 40 50 60 70
Human plasma [ml]
so 90 100
Fig. 4 Elimination of calcium from 100 ml human plasma (initial
Ca content, 9.35 mg) concomitant with phosphate removal (cf.
fig-3).
Tab. 3 Electrolyte concentrations in sheep blood during an extra-
corporeal treatment with iron-dextran complex.
Electrolyte
P (mmol/1)
Fe ( / )
Ca (mmol/1)
Time (min)
0
1.94
2.65
2.52
15
0.03
2.63
2.87
30
0.03
2.75
2.54
45
0.13
2.79
2.64
60
0.06
2.40
3.29
75
0.06
2.72
2.85
Blood was pässed through a cartridge containing 250 ml of phos-
phate adsorbent; flow rate, 70^90 ml/min.
most patients with en&stage renal failure and rnany with
moderate tp marked renal insufficiency require phos-
phate binders. Their applicätion is necessary to avoid
skeletal pain, changes in bone mineralization, spontane-
ous ftactures, and calcium phosphate-like deposits in
soft tissues and blood vessels (25, 26). In recent years
it has been reported that the most seriously intoxicated
patients had been treated with dialysing fluid containing
high concentrations of aluminum and phosphate binders
containing aluminum (27-29). The dialysis dementia
syndrome was related to the increased concentration of
aluminum in the plasma and in the brain tissue (30, 31).
For that reason many authors propagated the oral appli-
cätion of aluminum-free compounds such äs calcium
carbonate or calcium acetate (32, 33). However, medica-
tion with the latter is associated with gastro-intestinal
Problems and a high risk of hypercalcaemia (10).
From these considerations it follows that a more effec-
tive and safer treatment of hyperphosphataemia can be
achieved by extending the total dialysis time and by the
optional applicätion of aluminum-free phosphate bind-
ers. Prolonging dialysis time, however, is not applicable
äs it additionally Stresses the patient. Instead, the desired
systemic reduction of phosphate should be achieved by
using, in addition to and simultaneously with conven-
tional haemodialysis, an adsorbent which specifically re-
moves the excess phosphate. To be clinically usefül,
such an adsorbent has to be integrated into the extracor-
poreal perfusion System and must be capable of elimi-
nating phosphate directly from whole blood. Extracor-
poreal removal of excess inorganic phosphate is espe-
cially of interest for patients who refuse phosphate-
lowering medication because of personal discomfort.
For a potentially chronic applicätion such a procedure
must be free of even minor side effects. In addition, it
should permit a blood flow of at least 100 ml/min.
Eur. J. Clin. Chem. Clin. Biocbem. / Vol. 32,1994 /No. 10
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We therefore recently developed a new phosphate bind-
ing agent (13). A porous, highly crosslinked and insolu-
ble dextran was complexed with polynuclear iron oxide-
hydroxide (FeOOH) centres. With the exception of a
non-porous agarose chromatography support described
by Hjerten (34), only soluble complexes between iron
hydroxide and mono- and polysaccharides have pre-
viously been prepared (35, 36). Such complexes, e. g.
with polymaltose (Ferrum-Hausmann™), are used for
the therapeutic treatment of iron deficiency anaemias in
humans and animals (37, 38). Structural studies on solu-
ble iron oxide-hydroxide complexes showed that they
form chainlike, polynuclear condensation products (39)
and that iron is present äs tetragonal ß-FeOOH (40).
Structure characterization of the newly synthesized,
amorphous, insoluble iron-dextran complexes is less
complete. Nevertheless, the ESCA and Mössbauer
spectra confirm that only high-spin ferne irons with ox-
ygen ligarids (sugar OH groups, water, hydroxide ions,
- bridges) are present. The most typical iron mass
Proportion of about 200 g/kg found in the dry material
suggests that each iroii(III) centre is statistically coordi-
nated to one glucose moiety (glucose-Fe(OH)3, Fe =
195 g/kg). In fact, the magnetic susceptibility and its
temperature dependence, measured in the ränge from 4
to 300 K, are very similar to a soluble, stoichiometric
Fe-glucose complex (35).
A few reports describe the interaction of phosphate with
iron-containing compounds (34, 37, 41, 42). Addition of
phosphate, even in small amounts, may lead to strong
effects, for example increased viscosity in iron-polymal-
tose Solutions (37). FeOOH-modified non-porous agar-
ose has been saturated with phosphate and used in this
form äs ion exchanger for the chromatography of pro-
teins (34).
The adsorbent described here is, to our knowledge, the
first one that specifically removes inorganic phosphate
and which fulfils the criteria for an application in an
extracorporeal blood perfiision System. The high binding
capacity of the adsorbent guarantees an efficient elimi-
nation of phosphate during haemodialysis. The patho-
logical excess of about 130 mmol of phosphate per week
in patients with end^stage renal failure, for example,
would be elimiriated düring the common three dialysis
sessions by an additional, integrated phosphate adsorp-
tion apheresis using a cartridge packed with 450 ml of
the new adsorbent.
On-line apheresis has the extra advantage that it can be
precisely controlled by adjusting the eartridge size (i. e.
total phosphate binding capacity) to the blood völume.
Material costs can be significantly reduced by repeated
regeneration and re^use of the adsorbent. Iii this context
it was shown that regeneration by a simple treatment
with NaOH did not cäuse a decrease of the phosphate
binding capacity. The described in vivo experiments
with sheep revealed no side efFects. Concomitant
calcium depletion can be compensated by dialysis. Ide-
ally, it may be expected that oral phosphate binders can
be avoided and no other measures have to be taken.
In conclusion, the newly developed iron(III) oxide-hy-
droxide modified dextran is suitäble for the selective
elimination of inorganic phosphate from whole blood.
The excellent phosphate elimination capacity and blood
compatibility make it attractive for the extracorporeal
treatment of hyperphosphataemia in acüte and chronic
renal failure.
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